| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1101834731 |
| P356 | DOI | 10.1038/S41434-017-0001-8 |
| P698 | PubMed publication ID | 29599530 |
| P2093 | author name string | Yang Liu | |
| Jing Nie | |||
| Yao Wang | |||
| Wen-Ying Zhang | |||
| Qing-Ming Yang | |||
| Chun-Meng Wang | |||
| Zhi-Qiang Wu | |||
| Wei-Dong Han | |||
| Han-Ren Dai | |||
| Ye-Lei Guo | |||
| P2860 | cites work | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia | Q29617590 | ||
| Managing cytokine release syndrome associated with novel T cell-engaging therapies. | Q33993517 | ||
| Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene | Q35839860 | ||
| Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia | Q36110355 | ||
| Definition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance | Q36153492 | ||
| Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation | Q36229698 | ||
| CAR-T Cell Therapy for Lymphoma. | Q36519358 | ||
| Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition | Q37137924 | ||
| DNA demethylating agent decitabine broadens the peripheral T cell receptor repertoire | Q37437334 | ||
| Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia | Q37442731 | ||
| Global Manufacturing of CAR T Cell Therapy | Q37717884 | ||
| Cellular immunotherapy for patients with reactivation of JC and BK polyomaviruses after transplantation | Q38220648 | ||
| Engineered T cells: the promise and challenges of cancer immunotherapy. | Q38828829 | ||
| At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies | Q38880268 | ||
| Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. | Q38913549 | ||
| Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells | Q38936086 | ||
| Virus-induced non-specific signals cause cell cycle progression of primed CD8(+) T cells but do not induce cell differentiation | Q40932915 | ||
| Induction of bystander T cell proliferation by viruses and type I interferon in vivo | Q46486509 | ||
| Retroviruses as mutagens: Insertion and excision of a nontransforming provirus alter expression of a resident transforming provirus | Q53570869 | ||
| P577 | publication date | 2018-03-29 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. |
Search more.